Literature DB >> 17189645

Prostate cancer chemoprevention: current status and future prospects.

Sanjay Gupta1.   

Abstract

Chemoprevention is a strategy that aims to reduce the incidence and burden of cancer through the development of agents to prevent, reverse or delay the carcinogenic process. Prostate cancer is a suitable target for prevention because it has a high incidence and prevalence, as well as a long latency and disease-related mortality, and furthermore it is a disease in which lifestyle and environmental factors may play critical roles. The development of chemoprevention strategies against prostate cancer will have a huge impact, both medically and economically. Large-scale clinical trials suggest that some agents such as selenium, lycopene, soy, green tea, vitamins D and E, anti-inflammatory and inhibitors of 5alpha-reductase are effective in preventing prostate cancer. Although each agent has the potential to affect the natural history of the disease, it is important to develop strategies to strategically proceed for the design and selection of test agents in order to demonstrate clinical benefit with the minimum of adverse effects. Appropriate selection of agent(s), disease stage, trial design and endpoints is critical in selecting the most promising regimens to accomplish these goals. This review highlights the present status of prostate cancer chemoprevention and discusses future prospects for chemopreventive strategies that are safe and clinically beneficial.

Entities:  

Mesh:

Year:  2006        PMID: 17189645     DOI: 10.1016/j.taap.2006.11.008

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  7 in total

Review 1.  Apigenin: a promising molecule for cancer prevention.

Authors:  Sanjeev Shukla; Sanjay Gupta
Journal:  Pharm Res       Date:  2010-03-20       Impact factor: 4.200

2.  Plant flavone apigenin: An emerging anticancer agent.

Authors:  Eswar Shankar; Aditi Goel; Karishma Gupta; Sanjay Gupta
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

3.  Protection against oxidative DNA damage and stress in human prostate by glutathione S-transferase P1.

Authors:  Rajnee Kanwal; Mitali Pandey; Natarajan Bhaskaran; Gregory T Maclennan; Pingfu Fu; Lee E Ponsky; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2012-07-25       Impact factor: 4.784

4.  Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer.

Authors:  Moammir H Aziz; Nancy E Dreckschmidt; Ajit K Verma
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

Review 5.  Epidemiology of Prostate Cancer.

Authors:  Prashanth Rawla
Journal:  World J Oncol       Date:  2019-04-20

6.  Antiproliferative and apoptotic activity of glycyrrhizinic acid in MCF-7 human breast cancer cells and evaluation of its effect on cell cycle, cell migration and m-TOR/PI3K/Akt signalling pathway.

Authors:  Zhen Zhang; Yun Feng; Zhen-Yu Li; Xiao-Zhong Cao
Journal:  Arch Med Sci       Date:  2018-11-08       Impact factor: 3.318

7.  Lycorine is a novel inhibitor of the growth and metastasis of hormone-refractory prostate cancer.

Authors:  Meichun Hu; Shihong Peng; Yundong He; Min Qin; Xiaonan Cong; Yajing Xing; Mingyao Liu; Zhengfang Yi
Journal:  Oncotarget       Date:  2015-06-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.